Hemoglobin Electrophoresis in Sickle Cell Trait with Thalassemia Compound Heterozygotes

Introduction to Sickle Cell Trait

In individuals with sickle cell trait who are compound heterozygotes for thalassemia, hemoglobin electrophoresis shows HbS levels below 35%, HbA levels around 65%, and microcytosis with reduced MCV, distinguishing them from typical sickle cell trait where HbS is 30-40% and HbA is 55-65% 1

Standard sickle cell trait without thalassemia shows HbA levels of 55-65%, HbS levels of 30-40%, HbF levels of less than 1%, and HbA2 levels of less than 3-5%, with normal MCV and MCH 1
This represents a benign carrier state that is mostly asymptomatic except at extremes of physiology, according to the American College of Physicians 2

When beta-thalassemia combines with sickle cell trait, HbA levels vary from 10-25%, HbS levels are 70-80%, HbA2 levels are elevated above 3-5%, and HbF may be elevated to less than 3% 1, 2
This represents a mild clinical phenotype of sickle cell disease, not just trait, requiring disease-specific management, as recommended by the American Society of Hematology 1, 2

When beta-zero thalassemia combines with sickle cell trait, no HbA is present, HbS levels are 80-90%, HbF levels are 5-15%, and HbA2 levels are above 3-5% 1, 2
This creates a severe clinical phenotype resembling HbSS disease with early painful crises and severe anemia, according to the National Heart, Lung, and Blood Institute 1, 2, 3

Sickle beta-thalassemia compound heterozygotes are not benign carriers but have actual sickle cell disease requiring disease-specific management, despite the presence of some HbA in the beta+ variant, as stated by the American College of Physicians 1, 2, 3

When transfusion is necessary, the target hemoglobin should be 100 g/L (10 g/dL) and blood products must be HbS-negative, Rh and Kell antigen matched, with extended phenotype matching to prevent alloimmunization, and hemoglobin should not be increased by more than 40 g/L in a single transfusion episode to avoid hyperviscosity 4

Patients with sickle beta-thalassemia should avoid precipitating factors such as nitrates, dapsone, local anesthetics (benzocaine, prilocaine), and sulfonamides, and may be treated with hydroxyurea, analgesics, antibiotics, and ACE inhibitors as clinically indicated, with aggressive preventive measures perioperatively similar to HbSS patients 5
First-degree relatives of patients with sickle beta-thalassemia should be tested and the entire family should receive genetic counseling as this is a disease of high health impact with autosomal recessive inheritance 5